Renal and hematologic toxicity profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT): A retrospective cohort study Perfil de toxicidad renal y hematológica de la terapia con radioligandos dirigida al PSMA marcada con 177Lu (177Lu-PSMA-RLT): estudio de cohorte retrospectivo
Revista Espanola de Medicina Nuclear e Imagen Molecular, cilt.45, sa.5, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 45 Sayı: 5
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.remn.2026.500306
- Dergi Adı: Revista Espanola de Medicina Nuclear e Imagen Molecular
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, DIALNET
- Anahtar Kelimeler: Radioligand therapy, Nephrotoxicity, Hematological toxicity, Prostate cancer, Lu-177-PSMA
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective This study aims to retrospectively evaluate the renal and hematologic toxicity profile of 177Lu-PSMA-RLT in patients with metastatic castration-resistant prostate cancer. Methods Renal function (GFR, BUN, and creatinine) and hematological parameters (hemoglobin, leukocyte, platelet) before and after treatment were examined in 41 patients who received 177Lu-PSMA-RLT at our clinic, and changes along with toxicity grades were determined. Additionally, pre-treatment PSMA PET/CT findings and other demographic and clinical data were assessed. Results In terms of renal toxicity, G0-G1 level toxicity was observed in 97.6% of cases, while G2 toxicity was observed in only one patient. This patient already had a low GFR before treatment and experienced only a 3-unit decrease. Regarding hematological toxicity, the rates of G3-4 toxicity were as follows: leukocytes 7.3%, hemoglobin 9.8%, platelets 7.3%. Conclusion No clinically significant nephrotoxicity was observed with 177Lu-PSMA-RLT. Hematologic toxicity is significant but manageable, and severe side effects are rare and within predictable limits.